A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Year: 2022

Publisher: Glob Reg Health Technol Assess

Abstract: Hereditary angioedema (HAE) is a rare genetic disease that impairs quality of life and can be fatal. The aim of this study was to apply a multi-criteria decision analysis (MCDA) to assess the value of three long-term prophylactic (LTP) therapies for HAE in Spain.

A multidisciplinary committee of 10 experts assessed the value of lanadelumab (subcutaneous use), C1 inhibitor (C1-INH; intravenous) and danazol (oral), using placebo as comparators. The EVIDEM methodology, which considers a set of 13 quantitative criteria, was followed. Lanadelumab was perceived as a high value-added intervention over C1-INH and danazol.

Keywords: Drugs evaluation, Hereditary angioedema, Lanadelumab, Multicriteria decision analysis (MCDA), Rare disease

How to cite: Zozaya, N., Caballero, T., González-Quevedo, T., Gamboa Setien, P., González, M. Ángeles ., Jódar, R. ., Poveda-Andrés, J. L. ., Guillén-Navarro, E. ., Rivero Cuadrado, A. ., & Hidalgo-Vega, Álvaro. (2022). A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain. Global & Regional Health Technology Assessment, 9(1), 14–21. https://doi.org/10.33393/grhta.2022.2333